In 2013, a comprehensive Canada-wide needs assessment revealed that over 25% of Canadian physicians were uncomfortable with the diagnosis and treatment of TD and identified significant knowledge gaps related to patient management. 4 To address the knowledge gaps, the Canadian Clinical Practice Guideline on the Diagnosis and Management of Testosterone Deficiency Syndrome in Adult Males was published in the CMAJ. 5 As part of its mandate, the guideline was offered as a "living document," to be updated periodically in a perpetual effort to incorporate advances in scientific and clinical discovery. The current CUA guideline was approached in this spirit and serves as an educational tool that builds on existing knowledge and offers a contemporary update to the literature.
MethodsThe current guideline is structured as a series of Questions & Answers (Q&A) relating to the diagnosis and management of TD. By way of this structure, the guideline offers a practical, evidence-based overview and recommendations related to the diagnosis, treatment, monitoring, risks and benefits of TD and testosterone therapy. It was designed to be a straightforward and user-friendly guide for specialists (urologists, endocrinologists, psychiatrists, geriatricians), general practitioners and the patients they treat. The guideline offers Canadian-specific content with respect to knowledge and attitudes related to TD, laboratory diagnostic testing, Health Canada approved treatment formulations and funding considerations.The authorship group represents a panel of Canadian and international experts in the fields of men's health and TD. Representation is inter-provincial and multi-disciplinary covering the fields of urology, internal medicine/endocrinology and clinical biochemistry.Relevant publications on TD and testosterone therapy were sought using a combination of Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and PubMed searches. The search strategy involved a series of key words including: testosterone deficiency, hypogonadism, low testosterone, androgen deficiency, andropause and testosterone replacement therapy. Filters included English language, human studies and an index date up to December 1, 2020. Recently published guidelines from the Canadian Men's Health Foundation, American Urological Association, The Endocrine Society and the European Association of Urology were included as supportive, summative content. [5][6][7][8][9] Whenever possible, guideline statements and recommendations have been assigned levels of evidence (LE) based on the GRADE Working Group framework (LE: high, moderate, low, very low quality of evidence). 10 In brief, randomized controlled trials were initially rated as highquality and observational studies as low-quality evidence. Additionally, the strength or importance of the recommendations was also graded as either "strong" or "weak" based on the quantity, quality, and consistency of the evidence available.Following a systematic search, panel members were asked to review the identif...